European Commission Calls for Data on Ingredients with Potential Endocrine-Disrupting Properties
endocrine disruptors
Substances classified as endocrine disruptors are compounds that can alter the functioning of the endocrine system and negatively affect the health of humans and animals. In 2019, the European Commission set out two lists of ingredients suspected of having endocrine disrupting properties. More recently, the Commission has published a call for data for 10 ingredients that were included in the low priority group (Group B) for the SCCS to be able to assess their safety.
Picture of Liliana Teles

Liliana Teles

Regulatory Affairs Manager
Linkedin Instagram Facebook Address-card

ENDOCRINE DISRUPTOR AND EU LEGAL FRAMEWORK

Endocrine disruptors are chemical substances of synthetic or natural origin that adversely affect the health of people and animals by altering the functioning of the endocrine system. The EU legislation broadly accepts the definition of endocrine disruptors used by the International Programme on Chemical Safety/World Health Organization (IPCS/WHO). It is the basis for the criteria used to identify endocrine disruptors under the Plant Protection Products Regulation and Biocidal Products Regulation.

Since the 1990’s, there has been a growing concern on endocrine disruptors. Significant progress in understanding and regulating endocrine disruptors has been made. In fact, the EU has been recognized as one of the global leaders in dealing with these chemicals, as well as being among the most protective legislations in the world.

There are sector-specific regulations and consequently different regulatory approaches to managing the risks posed by endocrine disruptors. In order to make sure that the EU legislation is coherent in this area and whether the legislation is effective at the protection of human health and the environment (identifying and minimizing exposure to these chemicals), the Fitness Check on endocrine disruptors was developed by the European Commission.

Although the Commission does not have specific provision on endocrine disruptors, it provides a regulatory framework with the aim to ensure a high level of protection of human health (European Cosmetics Regulation No. 1223/2009). The EU approach is based on high-level scientific advice from the relevant EU risk assessment bodies, like the European Chemicals Agency (ECHA), the European Food Safety Authority (EFSA) or the Scientific Committee on Consumer Safety (SCCS).

The Cosmetics Regulation lays down a system of restrictions and bans on the use of certain substances in cosmetics based on a scientific risk assessment carried out by the SCCS, in order to address potential risks for human health. Concerns regarding endocrine-disrupting properties of substances (used in cosmetics) are also addressed in the SCCS’ risk assessment.

In early 2019, a priority list of 28 potential endocrine disruptors (not already covered by the bans of cosmetic regulation) was established by the Commission. From these 28 substances, 14 were considered as higher priority (Group A) and the other 14 were included in the low priority group (Group B).

The substances included in Group B were ingredients that were not undergoing substance evaluation under REACH or that its substance evaluation showed that it only raises environmental concern (not a human health one). In this Group were also included substances that have been recently evaluated by the SCCS and found safe and/or substances that have been recently classified as CMRs under CLP (where corresponding risk assessment/management measures are in place to prohibit/restrict their use in cosmetic products).

EUROPEAN COMMISSION CALL FOR DATA ON 10 INGREDIENTS

The European Commission has called for data on ingredients with potential endocrine-disrupting properties used in cosmetic products. The Commission invited any interested parties (academic and other research institutes, EU countries’ authorities, manufacturers, producers of the substances, consumers associations) to submit any scientific relevant information on the following substances:

  • Butylparaben (CAS No: 94-26-8)
  • Methylparaben (CAS No: 99-76-3)
  • Ethylhexyl Methoxycinnamate (EHMC)/Octylmethoxycinnamate (OMC)/Octinoxate (CAS No: (5466-77-3/-/83834-59-7)
  • Benzophenone-1 (BP-1) (CAS No: 131-56-6)
  • Benzophenone-2 (BP-2) (CAS No: 131-55-5)
  • Benzophenone-4 (BP-4) (CAS No: 4065-45-6)
  • Benzophenone-5 (BP-5) (CAS No: 6628-37-1)
  • BHA/Butylated hydroxyanisole/tert-butyl-4-hydroxyanisole (CAS No: 25013-16-5)
  • Triphenyl Phosphate (CAS No: 115-86-6)
  • Salicylic Acid (CAS No: 69-72-7)

A period of consultation for all substances, except Butylparaben, was set from 15 February to 15 November 2021. For Butylparaben the period of consultation began at the same date but ended on July 15th (2021). Last year, this last ingredient has been included in the Candidate List of Substances of Very High Concern (SVHCs) and, consequently, it is a more ‘urgent’ ingredient to be evaluated. See our previous post for more information.

The relevant scientific data requested may include data regarding all physicochemical properties, toxicokinetic and toxicological endpoints, assessment of exposure through consumer products and/or an indication of the suggested safe concentration limits for the substances listed in Group B. The data submitted should be in line with the SCCS notes of Guidance (10th revision).

After receiving sufficient data, the Commission will request the SCCS to evaluate the substances without delay. In accordance to the SCCS opinion, the Commission will take appropriate action to prohibit or restrict the use of the different ingredients in cosmetic products.

If you have any question regarding this or other subjects related to the EU Cosmetic Regulation, do not hesitate to contact us at info@criticalcatalyst.com.

References:

  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products
  2. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions; Towards a comprehensive European Union framework on endocrine disruptors. European Commission. Brussels, 7.11.2018. Available at: https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1553707706598&uri=CELEX:52018DC0734
  3. Report from the Commission to the European Parliament, the Council and the European Economic and Social Committee, in accordance with Article 138(7) of REACH to review if the scope of Article 60(3) should be extended to substances identified under Article 57(f) as having endocrine disrupting properties with an equivalent level of concern to other substances listed as substances of very high concern. European Commission. Brussels, 20.12.2016. Available at: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52016DC0814&from=EN
  4. Call for data on ingredients with potential endocrine-disrupting properties used in cosmetic products. European Commission. 2019. Available at: https://ec.europa.eu/growth/content/call-data-ingredients-potential-endocrine-disrupting-properties-used-cosmetic-products_en

further
reading
medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
Guilherme Semedo February 24, 2023
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
Guilherme Semedo February 15, 2023
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
Guilherme Semedo February 13, 2023
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
Guilherme Semedo January 9, 2023
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
Guilherme Semedo December 13, 2022
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
Liliana Teles December 10, 2022
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
Filipa Ferreira October 11, 2022
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »
Filipa Ferreira October 4, 2022

services

CONTACT US

  • info@criticalcatalyst.com
  • +351 91 200 43 51
    PT mobile network call
  • EUROPEAN UNION (HQ)
    679 Avenida da República
    4450-242 Matosinhos (PT)
  • UNITED KINGDOM
    49 Queen Victoria Street
    EC4N 4SA London (UK)